PMID- 17100568
OWN - NLM
STAT- MEDLINE
DCOM- 20061204
LR  - 20220328
IS  - 1873-5576 (Electronic)
IS  - 1568-0096 (Linking)
VI  - 6
IP  - 7
DP  - 2006 Nov
TI  - Protein kinases as drug targets in cancer.
PG  - 623-34
AB  - Identification of the key roles of protein kinases in signaling pathways leading 
      to development of cancer has caused pharmacological interest to concentrate 
      extensively on targeted therapies as a more specific and effective way for 
      blockade of cancer progression. This review will mainly focus on inhibitors 
      targeting these key components of cellular signaling by employing a 
      technology-based point of view with respect to ATP- and non-ATP-competitive small 
      molecule inhibitors and monoclonal antibodies of selected protein kinases, 
      particularly, mammalian target of rapamycin (mTOR), BCR-ABL, MEK, p38 MAPK, EGFR 
      PDGFR, VEGFR, HER2 and Raf. Inhibitors of the heat shock protein Hsp90 are also 
      included in a separate section, as this protein plays an essential role for the 
      maturation/proper activation of cancer-related protein kinases. In the following 
      review, the molecular details of the mode of action of these inhibitors as well 
      as the emergence of drug resistance encountered in several cases are discussed in 
      light of the structural, molecular and clinical studies conducted so far.
FAU - Arslan, Mehmet Alper
AU  - Arslan MA
AD  - Biological Sciences and Bioengineering Program, Sabanci University, Orhanli-Tuzla 
      34956, Istanbul, Turkey.
FAU - Kutuk, Ozgur
AU  - Kutuk O
FAU - Basaga, Huveyda
AU  - Basaga H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Cancer Drug Targets
JT  - Current cancer drug targets
JID - 101094211
RN  - 0 (2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Benzamides)
RN  - 0 (Benzenesulfonates)
RN  - 0 (HSP90 Heat-Shock Proteins)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Pyrimidines)
RN  - 0 (Quinazolines)
RN  - 25X51I8RD4 (Niacinamide)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - P188ANX8CK (Trastuzumab)
RN  - S65743JHBS (Gefitinib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Benzamides/pharmacology
MH  - Benzenesulfonates/therapeutic use
MH  - Gefitinib
MH  - HSP90 Heat-Shock Proteins/antagonists & inhibitors
MH  - Humans
MH  - Imatinib Mesylate
MH  - Neoplasms/*drug therapy/enzymology
MH  - Niacinamide/analogs & derivatives
MH  - Phenylurea Compounds
MH  - Piperazines/therapeutic use
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Pyridines/therapeutic use
MH  - Pyrimidines/therapeutic use
MH  - Quinazolines/therapeutic use
MH  - Signal Transduction
MH  - Sirolimus/therapeutic use
MH  - Sorafenib
MH  - Trastuzumab
MH  - p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
RF  - 94
EDAT- 2006/11/15 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/11/15 09:00
PHST- 2006/11/15 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/11/15 09:00 [entrez]
AID - 10.2174/156800906778742479 [doi]
PST - ppublish
SO  - Curr Cancer Drug Targets. 2006 Nov;6(7):623-34. doi: 10.2174/156800906778742479.